Clinical presentation of COVID-19 in patients with inflammatory bowel disease: a systematic review and meta-analysis
- Author:
Anupam K. SINGH
1
;
Anuraag JENA
;
Praveen KUMAR-M
;
Daya Krishna JHA
;
Vishal SHARMA
Author Information
- Publication Type:Original Article
- From:Intestinal Research 2022;20(1):134-143
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background/Aims:Coronavirus disease 2019 (COVID-19) is recognized to have variable clinical manifestations. The clinical presentation of patients with inflammatory bowel disease (IBD) having COVID-19 is unclear.
Methods:We identified articles reporting about the clinical presentation of COVID-19 in those with underlying IBD from PubMed and Embase. The studies, irrespective of design or language, were included. The overall pooled frequency of various symptoms was estimated. Joanna Briggs Institute Critical appraisal checklist was used to assess the quality of studies.
Results:Eleven studies, including 1,325 patients, were included in the pooled analysis. The pooled estimates for clinical presentation were; fever: 67.53% (95% confidence interval [CI], 45.38–83.88), cough: 59.58% (95% CI, 45.01–72.63), diarrhea: 27.26% (95% CI, 19.51–36.69), running nose: 27% (95% CI, 15.26–43.19) and dyspnea: 25.29% (95% CI, 18.52–33.52). The pooled prevalence rates for abdominal pain, nausea and vomiting were 13.08% (95% CI, 9.24–18.19), 10.08% (95% CI, 5.84–16.85) and 8.80% (95% CI, 4.43–16.70) per 100 population, respectively.
Conclusions:The clinical presentation of COVID-19 in IBD patients is similar to the general population.
